The bBHC-Stem Cell Treatment & Research Institute (STRI) is at the forefront of stem cell research, focusing on the development of nEPS, a novel pluripotent stem cell technology. This innovative cell type is designed to be mass-producible and is touted for its lack of side effects, positioning it as a groundbreaking advancement in regenerative medicine. STRI's research encompasses a wide range of applications, including treatments for nervous system diseases, diabetes, liver disease, cancer, autoimmune diseases, kidney disease, cartilage repair, and skin cell rejuvenation. The institute emphasizes its commitment to scientific discovery aimed at benefiting the global community, with a vision of extending healthy lifespans significantly.

In addition to its research initiatives, STRI operates an approved cell processing facility and is recognized as a human cell care provider by the Korean Food and Drug Administration (KFDA). This regulatory approval underscores the institute's dedication to maintaining high standards in its stem cell treatments and research practices. STRI's mission is not only to advance scientific knowledge but also to translate these discoveries into practical solutions that enhance human health and longevity, ultimately striving to make the vision of living a healthy life well into advanced age a reality.

South Korea

bBHC Stem Cell Treatment & Research Institute discovered the newly Elicited pluripotent Stem Cell without side effects which is called nEPS. We've been differentiated nEPS into endoderm,mesoderm and ectoderm. Our goal is overcome to incurable diseas using in nEPS.

bBHC-Stem Cell Treatment & Research Institute

Company Details